- CA$74.51m
- CA$69.60m
- $13.66m
- 52
- 15
- 31
- 24
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 13.2 | ||
| Price to Tang. Book | 13.2 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 3.97 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -86.49% | ||
| Return on Equity | -89.55% | ||
| Operating Margin | -27.85% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | 0.01 | 0.2 | 2.56 | 13.66 | n/a | n/a | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Innocan Pharma Corporation is an Israel-based pharmaceutical company active in the medical cannabis industry. It operates through three distinct operating segments: Research, Development, Marketing, Distribution and sales of InnoCan-branded over the counter (OTC) pharmaceutical products; Research and Development of Non-pharmaceutical products for third parties and Research and Development of hydrogels containing liposomes intended for licensing or sale to third party pharmaceutical corporations for manufacturing, distribution and sales. The Company is developing an OTC topical treatments product line and new platform to facilitate the targeted controlled administration of cannabinoids via injection.
Directors
- Last Annual
- December 31st, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- May 31st, 2018
- Public Since
- September 24th, 2019
- No. of Employees
- 8
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
Canadian Securities Exchange- Shares in Issue
- 275,954,735
- Address
- 10 Hamenofim Street, HERZLIYA, 4672561
- Web
- https://innocanpharma.com/
- Phone
- Auditors
- BDO Ziv Haft
Upcoming Events for INNO
Similar to INNO
1933 Industries
Canadian Securities Exchange
1CM
Canadian Securities Exchange
Acreage Holdings
Canadian Securities Exchange
Adastra Holdings
Canadian Securities Exchange
Aion Therapeutic
Canadian Securities Exchange
FAQ
As of Today at 19:11 UTC, shares in Innocan Pharma are trading at CA$0.27. This share price information is delayed by 15 minutes.
Shares in Innocan Pharma last closed at CA$0.27 and the price had moved by +17.39% over the past 365 days. In terms of relative price strength the Innocan Pharma share price has outperformed the Toronto Stock Exchange 300 Composite Index by +11.39% over the past year.
There is no consensus recommendation for this security.
Innocan Pharma does not currently pay a dividend.
Innocan Pharma does not currently pay a dividend.
Innocan Pharma does not currently pay a dividend.
To buy shares in Innocan Pharma you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of CA$0.27, shares in Innocan Pharma had a market capitalisation of CA$74.51m.
Here are the trading details for Innocan Pharma:
- Country of listing: Canada
- Exchange: CNX
- Ticker Symbol: INNO
Based on an overall assessment of its quality, value and momentum Innocan Pharma is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
We could not find analyst target price data for this security.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Innocan Pharma. Over the past six months, its share price has underperformed the Toronto Stock Exchange 300 Composite Index by -25.14%.
As of the last closing price of CA$0.27, shares in Innocan Pharma were trading -10.63% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Innocan Pharma PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at CA$0.27.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
We do not have data on Innocan Pharma's directors